TIDMSHP
SHIRE PROPOSES COMBINATION WITH BAXALTA TO CREATE THE LEADING GLOBAL BIOTECH
COMPANY FOCUSED ON RARE DISEASES
Strong strategic fit and industry-leading portfolio of combined company is
projected to deliver immediate value creation and generate $20 billion in
product sales by 2020
* Complementary capabilities create leading platform for growth, with over 30
planned product launches and the industry's largest rare diseases portfolio
with 50-plus projects
* Transaction expected to generate double-digit top-line growth; strong
returns and attractive value creation; breakeven to Non GAAP EPS in year
one with accretion thereafter
* Combination offers significant operating synergy potential and a compelling
tax profile (projected 16%-17% combined Non GAAP effective tax rate by
2017), generating an IRR in excess of 10%
* All-stock transaction of approximately $30 billion represents immediate
value creation for Baxalta shareholders through a substantial premium of
36% and allows for participation in future upside
* Shire urges Baxalta to engage in a negotiated transaction
Dublin, Ireland - August 4, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) today
confirms that it made a proposal to Baxalta Incorporated (NYSE: BXLT) on July
10, 2015, to combine the companies in an all-stock transaction pursuant to
which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire
ADRs. The proposal implies a value of $45.23 per Baxalta share and represents a
significant premium of 36% over Baxalta's stock price as of August 3, 2015.
Baxalta has declined to engage in substantive discussions regarding the
proposal.
The proposed combination would generate immediate shareholder value and
accelerate the growth plans of both Shire and Baxalta. The combined entity
would be the global leader in rare diseases with multiple billion-dollar
franchises in high-value therapeutic areas with substantial barriers to entry.
Together, Baxalta and Shire are projected to deliver product sales of $20
billion in 2020, advancing the combined pipeline and bringing innovative new
therapies to market for patients with rare, often life-threatening, diseases
and conditions.
The proposed transaction would be structured as an all-stock transaction to
maintain the tax-free nature of Baxalta's July 1, 2015, spinoff from Baxter.
Baxalta shareholders would own approximately 37% of the combined Shire group.
Promptly after the close, Shire would initiate a share buy-back program to
repurchase, within two years, up to 13% of the combined post-transaction shares
outstanding, enhancing the earnings accretion of the transaction while
maintaining financial flexibility and an investment-grade credit profile.
Flemming Ornskov, Chief Executive Officer of Shire said: "We believe the
proposed combination of Shire and Baxalta would be strategically and
financially attractive for both of our companies, accelerating our respective
growth ambitions and creating the leading global biotech company in rare
diseases. The combined entity would have the opportunity to create significant
shareholder value in one of the most attractive and fastest growing segments in
healthcare. Together, the companies would be projected to deliver $20 billion
in product sales by 2020, with the financial and operational firepower to fuel
further innovation and growth in rare diseases. It is our strong preference to
immediately enter into a negotiated transaction to explore the full potential
of the proposed combination and finalize the terms of an agreement."
Susan Kilsby, Chairman of the Board of Shire, said: "Our Board unanimously
supports this combination with Baxalta. Following thorough analysis and
discussion, our Board concluded that this proposed transaction will deliver
significant value for shareholders. We urge Baxalta to engage with us to create
a stronger combined company that will benefit all of our stakeholders."
Proposed combination creates the global leader in rare diseases with compelling
financials and strong outlook
The global leader in rare diseases
* $20 billion in product sales by 2020 ("20x20")
* Multiple $1 billion plus high-value rare disease franchises with
substantial barriers to entry
* Complementary expertise in rare diseases R&D, commercial, and
manufacturing, supported by global scale and infrastructure
Compelling financial profile and value creation
* Projected double-digit top-line growth
* Substantial operating synergies
* Accretive to Non GAAP earnings; breakeven in year one, with accretion
thereafter, supported by a share buyback program
* Attractive sustainable returns including IRR in excess of 10%
Strong future outlook
* More than 30 new product launches planned with approximately $5 billion
incremental sales potential by 2020
* Strong balance sheet and robust pro forma cash flow support future organic
growth and M&A
Evercore and Morgan Stanley are acting as financial advisors to Shire and Ropes
& Gray LLP and Slaughter and May are acting as legal counsel.
Below is the text of a letter sent to the Chief Executive Officer of Baxalta on
August 4, 2015.
SUBJECT TO CONTRACT
August 4, 2015
Ludwig N. Hantson, Ph.D.
President and Chief Executive Officer
Baxalta Incorporated
One Baxter Parkway
Deerfield, IL 60015
Proposed Combination of Shire plc and Baxalta Incorporated
Dear Ludwig,
We continue to believe that a combination of Shire and Baxalta offers a
compelling opportunity that provides significant benefits to our respective
shareholders, employees, and the patients and physicians that we both serve.
We have sought to engage with you regarding such a combination since early
July. Other than a brief meeting on July 10th at which we outlined our proposal
and its benefits, your lack of engagement has been surprising. On July 31st,
weeks after receiving our written proposal and without any meaningful
interaction, you stated that you had concluded it was not a basis for
discussions. As a result, you have left us with no choice but to make our
proposal known to your shareholders. We believe they deserve an opportunity to
consider it.
As we have consistently articulated, we believe that a combination of our
businesses in an all-stock transaction provides your shareholders with both
substantial current value and long-term upside. A combination with Shire also
fully aligns with your articulated vision to become a leading Rare / Orphan
Diseases company. The benefits of our proposal include:
* Significantly accelerating the value and mitigating the risk of Baxalta's
standalone strategy while providing a substantial immediate premium to
Baxalta's current share price and participation in future upside;
* Strong expected operating synergies as well as benefits from our tax
structure to drive meaningful earnings accretion and provide an enhanced
growth profile relative to the standalone Baxalta strategy; and
* A stronger balance sheet that would provide financial flexibility and the
ability to launch a sizeable share buy-back program to enhance the capital
structure and further improve the per share earnings profile of the
combined company.
Our proposal of an all-stock combination of 0.1687 Shire ADRs for each Baxalta
share represents:
* a value of $45.23 per Baxalta share based on Shire's August 3, 2015 closing
price;
* a total enterprise value of $33.9 billion;
* a 36% premium to Baxalta's closing share price on August 3, 2015; and
* a 15x multiple of last twelve months EBITDA as of March 31, 2015.
These represent very attractive metrics relative to other all-stock
transactions of this size.
In addition, Baxalta shareholders would benefit from significant further upside
through their participation in the substantial synergies arising from the
combination. Assuming 680 million outstanding shares of Baxalta common stock on
a fully diluted basis, Baxalta's shareholders would hold approximately 37% of
the combined company.
Because the total consideration will be paid in our ADRs, we believe the
tax-free nature of the separation of Baxalta from Baxter will not be
jeopardized, and you will be able to meet your related obligations to Baxter
under the separation agreements. To that end, we have not discussed this
potential transaction with Baxter, and we waited until the separation occurred
before contacting you.
We have engaged and have been working closely with Evercore Group L.L.C. and
Morgan Stanley & Co as financial advisors, and Ropes & Gray LLP and Slaughter
and May as legal counsel. As explained in our July 10th letter, we have
completed an extensive analysis of Baxalta and have carefully considered the
proposed combination on the basis of publicly available information. We do not
believe that there are any regulatory or other impediments to consummation of
the proposed transaction. We believe we could complete our confirmatory due
diligence and finalize the terms of a combination expeditiously. The proposed
transaction is subject to such matters and satisfaction of customary closing
conditions.
Given the substantial value represented by our proposal and the compelling
benefits of a combination, we urge you to engage with us without any further
delay.
Sincerely,
Flemming Ornskov
Chief Executive Officer
Shire plc
LIVE CONFERENCE CALL FOR INVESTORS:
Flemming Ornskov, MD, MPH, Chief Executive Officer, will host the investor and
analyst conference call at 1:30 PM BST/8:30 AM EDT.
The details of the conference call are as follows:
UK dial in: 0808 237 0030 or 0203 139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers: Click here
Password/Conf ID: 25841912#
Live Webcast: Click here
Replay:
A replay of the presentation will be available for two weeks by phone and by
webcast for three months. Details can be found on our Investor Relations
website http://investors.shire.com/.
FOR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
Media
Michele Galen mgalen@shire.com +1 781 482-1867
Gwen Fisher gfisher@shire.com +1 484 595 9836
Brooke Clarke brclarke@shire.com +44 1256 894829
FTI Consulting (Media Adviser to the Company)
Ben Atwell (London) ben.atwell@fticonsulting.com +44 20 3727 1000
David B. Roady (New York) david.roady@fticonsulting.com +1 212 850 5600
Robert Stanislaro (New robert.stanislaro@fticonsulting.com +1 212 850 5600
York)
Evercore (Financial Adviser to the Company)
Francois Maisonrouge maisonrouge@Evercore.com +1 212 857 3100
Morgan Stanley (Financial Adviser and Corporate Broker to the Company)
Michele Colocci michele.colocci@morganstanley.com +44 20 7425 8000
Peter Moorhouse peter.moorhouse@morganstanley.com +44 20 7425 8000
Deutsche Bank (Corporate Broker to the Company)
Ben Lawrence ben.lawrence@db.com +44 20 7545 8000
Evercore Partners International LLP ("Evercore"), which is authorised and
regulated by the Financial Conduct Authority in the United Kingdom, is acting
as financial adviser to Shire and no-one else in connection with the matters
referred to in this announcement and will not be responsible to anyone other
than Shire for providing the protections afforded to clients of Evercore or for
providing advice in relation to the contents of this announcement or any other
matters referred to herein.
Morgan Stanley & Co. International plc ("Morgan Stanley"), which is authorised
by the Prudential Regulation Authority and regulated by the Financial Conduct
Authority and the Prudential Regulation Authority in the United Kingdom, is
acting as financial adviser to Shire and no one else in connection with the
matters referred to in this announcement. In connection with such matters,
Morgan Stanley, its affiliates and its and their respective directors,
officers, employees and agents will not regard any other person as their
client, nor will they be responsible to any other person other than Shire for
providing the protections afforded to their clients or for providing advice in
connection with the contents of this announcement or any other matter referred
to herein.
Deutsche Bank AG is authorised under German Banking Law (competent authority:
European Central Bank) and, in the United Kingdom, by the Prudential Regulation
Authority. It is subject to supervision by the European Central Bank and by
BaFin, Germany's Federal Financial Supervisory Authority, and is subject to
limited regulation in the United Kingdom by the Prudential Regulation Authority
and Financial Conduct Authority. Details about the extent of its authorisation
and regulation by the Prudential Regulation Authority, and regulation by the
Financial Conduct Authority are available on request. Deutsche Bank AG, acting
through its London branch ("DB"), is acting as a corporate broker to Shire plc
and no other person in connection with the matters referred to in this
announcement. DB will not be responsible to any person other than Shire plc for
providing any of the protections afforded to clients of DB, nor for providing
any advice in relation to the matters referred to herein. Without limiting a
person's liability for fraud, neither DB nor any of its subsidiary
undertakings, branches or affiliates nor any of its or their respective
directors, officers, representatives, employees, advisers or agents owes or
accepts any duty, liability or responsibility whatsoever (whether direct or
indirect, whether in contract, in tort, under statute or otherwise) to any
person who is not a client of DB in connection with this announcement, any
statement contained herein or otherwise.
FORWARD-LOOKING STATEMENTS
Statements included herein that are not historical facts, including without
limitation statements concerning our proposed business combination with Baxalta
Incorporated ("Baxalta"), and the timing and benefits thereof, including our
20x20 ambition that targets $20 billion in combined product sales by 2020, as
well as other targets for future financial results, capital structure,
performance and sustainability of a combined company, and a combined company's
future strategy, plans, objectives, expectations and intentions, are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire could be materially adversely
affected. These risks and uncertainties include, but are not limited to, the
following:
* Baxalta will refuse to negotiate with Shire, and the parties will be
unsuccessful in negotiating a transaction;
* if a transaction is negotiated, the transaction may not be completed, due
to failure of closing conditions, including any shareholder approvals;
* the businesses may not be integrated successfully, that such integration
may be more difficult, time-consuming or costly than expected, or that the
expected benefits of the transaction may not be realized;
* disruption from the proposed transaction makes it more difficult to conduct
business as usual or maintain relationships with patients, physicians,
employees or suppliers;
* the combined company may not achieve some or all of the anticipated
benefits of Baxalta's spin-off from Baxter International, Inc. ("Baxter")
and the proposed transaction may have an adverse impact on Baxalta's
existing arrangements with Baxter;
* the failure to achieve the strategic objectives with respect to the
proposed combination with Baxalta adversely affects the combined company's
financial condition and results of operations;
* products and product candidates may not achieve commercial success;
* product sales from certain products, including ADDERALL XR and INTUNIV, are
subject to generic competition;
* the failure to obtain and maintain reimbursement, or an adequate level of
reimbursement, by third-party payers in a timely manner for the combined
company's products may adversely impact future revenues, financial
condition, and results of operations, particularly if there is systematic
pressure on pricing of products to treat rare diseases;
* supply chain or manufacturing disruptions may result in declines in revenue
for affected products and commercial traction from competitive;
* regulatory actions associated with product approvals or changes to
manufacturing sites, ingredients or manufacturing processes could lead to
significant delays, an increase in operating costs, lost product sales, an
interruption of research activities or the delay of new product launches;
* the successful development of the combined company's pre-commercial
products is highly uncertain and requires significant expenditures and
time, and these products may not receive regulatory approval;
* the actions of certain customers could affect the combined company's
ability to sell or market products profitably;
* investigations or enforcement action by regulatory authorities or law
enforcement agencies may result in significant legal costs and the payment
of substantial compensation or fines;
* adverse outcomes in legal matters and other disputes, including the
combined company's ability to enforce and defend patents and other
intellectual property rights required for its business, could have a
material adverse effect on the combined company's revenues, financial
condition or results of operations;
* the combined company may be unable to attract and/or retain the highly
skilled personnel needed to meet its strategic objectives; and
* other risks and uncertainties detailed from time to time in Shire's filings
with the Securities and Exchange Commission ("SEC"), including those risks
outlined in "Item 1A: Risk Factors" in Shire's Annual Report on Form 10-K
for the year ended December 31, 2014, which was filed with the SEC on
February 24, 2015, and Baxalta's filings with the SEC.
All forward-looking statements attributable to us or any person acting on our
behalf are expressly qualified in their entirety by this cautionary statement.
Readers are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof. Except to the extent
otherwise required by applicable law, we do not undertake any obligation to
republish revised forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
Third Party-Sourced Information
All information in this communication regarding Baxalta, including its
businesses, operations and financial results, was obtained from public sources.
While Shire has no knowledge that any such information is inaccurate or
incomplete, Shire has not verified any of that information.
Additional Information
This communication does not constitute an offer to buy or solicitation of any
offer to sell securities. This communication relates to a proposal which Shire
has made for a business combination transaction with Baxalta. In furtherance of
this proposal and subject to future developments, if Shire and Baxalta agree on
a negotiated transaction, Shire and Baxalta may file one or more registration
statements, tender offer statements, prospectuses, proxy statements or other
documents with the SEC. This communication is not a substitute for any
registration statement, prospectus, proxy statement or other document Shire and
/or Baxalta may file with the SEC in connection with the proposed transaction.
INVESTORS AND SECURITY HOLDERS OF SHIRE AND BAXALTA ARE URGED TO READ CAREFULLY
THE REGISTRATION STATEMENT(S), TENDER OFFER STATEMENT(S), PROSPECTUS(ES), PROXY
STATEMENT(S) AND OTHER DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SHIRE, BALXALTA AND THE
PROPOSED TRANSACTION. Investors and security holders may obtain free copies of
these documents (when they are available) and other related documents filed
with the SEC at the SEC's web site at www.sec.gov or by directing a request
to Shire's Investor Relations department at Shire plc, Attention: Investor
Relations, 300 Shire Way, Lexington, MA 02421 or to Shire's Investor Relations
department at +1 484 595 2220 in the U.S. and +44 1256 894157 in the UK or by
email to investorrelations@shire.com.
Certain Information Regarding Participants
Shire and its directors and executive officers may be deemed participants in
the solicitation of proxies in connection with the proposed transaction. You
can find information about Shire's directors and executive officers
in Shire's Annual Report on Form 10-K for the year ended December 31, 2014,
which was filed with the SEC on February 24, 2015. Additional information
regarding the special interests of these directors and executive officers in
the proposed transaction will be included in one or more registration
statements, tender offer statements, prospectuses, proxy statements or other
documents filed with the SEC if any when they become available. You may obtain
these documents (when they become available) free of charge at the SEC's web
site at www.sec.gov and from Investor Relations at Shire as described above.
This document shall not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the U.S. Securities Act of1933, as amended.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.
http://www.shire.com/
END
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024